Impact of H1 Antihistamines on Bacillus Calmette-Guerin-treated Non-muscle-invasive Bladder Cancer.

ABSTRACT:

Background and objective

Concomitant H1 antihistamine (H1-AH) administration is associated with better survival outcomes for patients with metastatic urothelial carcinoma receiving immunotherapy. However, the role of H1-AHs among patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacillus Calmette-Guérin (BCG) immunotherapy has not been explored. Our aim was to investigate the impact of H1-AH use on survival outcomes for patients with BCG-treated NMIBC.

Methods

We conducted a territory-wide retrospective observational study. Patients with NMIBC who received intravesical immunotherapy with a single BCG strain in Hong Kong from 2001 to 2020 were identified. H1-AH prescription data were recorded. Overall survival (OS), cancer-specific su

SUBMITTER: Liu K 

PROVIDER: S-EPMC12689218 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature